Utilizing Quantitative MRI and Biomarkers for MASLD Identification and Assessment

Overview

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults globally and poses significant risks for liver-related morbidity and mortality. This study evaluates the efficacy of quantitative MRI (qMRI) techniques alone and combined with laboratory and clinical biomarkers to non-invasively detect and stage MASLD, including fibrotic and advanced fibrosis stages.

Background

MASLD is characterized by hepatic fat accumulation in the presence of metabolic risk factors such as type 2 diabetes and obesity, progressing from steatosis to steatohepatitis, fibrosis, and cirrhosis. Liver biopsy remains the diagnostic gold standard but is invasive and prone to sampling errors and variability. Quantitative MRI techniques, including PDFF, MRE, DWI, and cT1 mapping, offer non-invasive alternatives to assess liver fat, inflammation, and fibrosis. Combining qMRI with clinical and laboratory biomarkers may improve diagnostic accuracy for MASLD staging.

Data Highlights

The study utilized data from the Amsterdam NAFLD-NASH cohort, including laboratory tests, vibration-controlled transient elastography (VCTE), and multiple qMRI modalities (PDFF, MRE, IVIM-DWI, cT1 mapping) in adults with hepatic steatosis. MRI parameters such as liver fat fraction, stiffness, elasticity, diffusion coefficients, and iron-corrected T1 values were quantified. Non-invasive biomarker scores like MR-MASH, MAST, and MEFIB were evaluated for their ability to identify metabolic steatohepatitis and fibrosis stages.

Key Findings

• qMRI techniques can non-invasively quantify hepatic steatosis, inflammation, and fibrosis, correlating with histological disease stages.
• PDFF effectively measures liver fat content, while MRE assesses fibrosis and tissue stiffness.
• Diffusion-weighted imaging (DWI) detects inflammation-related changes by measuring reduced diffusivity due to immune cell infiltration.
• Combining qMRI parameters with clinical biomarkers (e.g., AST, waist circumference) enhances diagnostic accuracy for identifying MASH and fibrotic MASLD.
• Non-invasive scores such as MR-MASH, MAST, and MEFIB integrate imaging and laboratory data to stratify disease severity and fibrosis stage.
• These combined approaches provide a promising alternative to liver biopsy for MASLD diagnosis and monitoring.

Clinical Implications

The integration of qMRI techniques with laboratory and anthropometric measurements offers a non-invasive, accurate method to diagnose and stage MASLD, reducing reliance on invasive liver biopsies. Clinicians can utilize combined imaging and biomarker scores to identify patients at higher risk for progressive liver disease, enabling timely intervention and monitoring. This approach supports personalized management strategies in metabolic liver disease.

Conclusion

Quantitative MRI combined with clinical and laboratory biomarkers provides a robust, non-invasive framework for detecting and staging MASLD, including fibrotic and advanced fibrosis stages. This methodology has the potential to improve patient care by facilitating early diagnosis and risk stratification without the drawbacks of liver biopsy.

References

1. Troelstra et al 2024 -- Quantitative MRI and Biomarkers in MASLD Assessment
2. Perspectum Ltd. -- LiverMultiScan® Protocol
3. Sinkus et al -- MR Elastography Methodology